Tumor Cells Recruit Macrophage Bodyguards to Outlast Chemotherapy

Tumor Cells Recruit Macrophage “Bodyguards” to Outlast Chemotherapy

What if cancer cells could recruit the body's own immune cells to help them survive treatment? Emerging research suggests that some tumors can interact with macrophages—immune cells that normally help defend and repair tissues—and reshape their behavior to support tumor survival.

In this article, we explore how tumor cells communicate with macrophages, how these immune cells can become part of the tumor microenvironment, and why this interaction may contribute to resistance to chemotherapy. Understanding these “macrophage bodyguards” could help researchers develop new strategies that target not only cancer cells themselves, but also the supportive environment that helps them persist.

Discover the science behind tumor–macrophage interactions, chemotherapy resistance, and the ongoing search for more effective cancer treatments.

When Cancer Turns the Immune System Into an Unexpected Ally

Imagine a city under attack. The police arrive, the streets are cleared, and the threat appears to be under control. But hidden among the crowd are people quietly helping the attackers rebuild, find shelter, and regroup.

Something surprisingly similar can happen inside a tumor.

Cancer cells do not live alone. They grow within a busy neighborhood of blood vessels, connective tissue, signaling molecules, and immune cells called the tumor microenvironment. Among the most important residents are macrophages—immune cells whose normal jobs include cleaning up damaged tissue, responding to injury, and helping coordinate repair.

In some tumors, cancer cells can influence these macrophages and turn them into tumor-associated macrophages (TAMs). Instead of strongly attacking the tumor, certain TAM populations can create conditions that help cancer cells survive, grow, spread, and sometimes become harder to eliminate with treatment.

That is where the idea of macrophages as cancer’s “bodyguards” comes from. It is a useful analogy—not a literal description—but it captures an important scientific concept: the cells surrounding a tumor can influence how well cancer treatment works.

Tumor-associated macrophages

What Exactly Are Macrophages?

Macrophages are part of the immune system and are found throughout the body. Think of them as adaptable maintenance and defense cells. They can engulf cellular debris, respond to signals from injured tissue, and communicate with other immune cells.

The important word is adaptable. Macrophages can change their behavior depending on the signals around them. Tumors can exploit this flexibility by producing chemical signals that attract macrophages and influence their functions. TAMs can therefore be highly diverse rather than one uniform type of immune cell.

This flexibility is one reason researchers are interested in macrophages as possible targets for cancer therapy.

How Does a Tumor Recruit Its “Bodyguards”?

Growing tumors release signaling molecules that can attract monocytes—the circulating cells that can develop into macrophages—toward the tumor. Signals such as CCL2, CCL5, and M-CSF have been implicated in macrophage recruitment and development within tumors.

Once inside the tumor environment, these cells encounter a very different set of instructions from those they would receive in healthy tissue. Oxygen levels, growth factors, cytokines, cancer-cell signals, and tissue damage can all influence macrophage behavior.

The result is a complicated relationship: the tumor can effectively create an environment in which some macrophages perform functions that benefit the cancer rather than the patient.

Who are the tumor-associated macrophages?

Macrophages are normally first responders: they engulf pathogens, clear debris, and coordinate immune attacks. But tumors are skilled at corrupting this system. Solid tumors recruit macrophages from two main sources — monocytes drawn in from the bloodstream by tumor-secreted chemokines, and resident macrophages already living in the tissue <cite index="6-1">which are important components of the tumor microenvironment (TME), with monocytes recruited to the tumor site by chemokines and other macrophages derived from tissue-resident cells inherent to the tumor site</cite>.

Once inside the tumor, macrophages don't stay neutral. <cite index="9-1,9-1">Within the tumor mass, tumor-associated macrophages have been shown to be fundamental for cancer progression</cite>, and in many solid tumors they are, by cell count, the single largest immune population present. Far from patrolling for threats, many of these macrophages are reprogrammed by the tumor into an "M2-like" state that suppresses immune attack and actively nurses cancer cells through treatment.

The evidence that TAMs matter for treatment outcomes is not just correlational. <cite index="2-1">Studies that experimentally deplete macrophages from tumors have repeatedly found that tumors become more sensitive to chemotherapy as a result</cite> — a strong signal that the macrophages themselves are actively blunting drug effects, rather than simply being bystanders in a resistant tumor.

How the Cancer bodyguards do their job

Researchers have mapped out several distinct tactics TAMs use to shield cancer cells from chemotherapy.

1. Chemical neutralization of the drug itself. 

In pancreatic cancer, TAMs secrete deoxycytidine, a molecule that directly interferes with gemcitabine's ability to trigger cell death, effectively defusing the drug before it can do damage <cite index="2-1">.</cite> Similar macrophage-driven resistance has been documented against other frontline chemotherapy agents, <cite index="2-1">including paclitaxel, doxorubicin, and etoposide</cite>.

2. Pumping the drug back out. 

Cancer cells often survive chemotherapy by expelling it through membrane transporter proteins. TAMs can help drive this process directly. In colorectal cancer, researchers recently traced a full signaling relay — <cite index="3-1">a CXCL17/CXCL22–CCR4–ATF6–GRP78 signaling axis running between macrophages and tumor cells</cite> — that promotes the drug-pump protein MRP1 to move to the tumor cell's surface, letting the cell flush out 5-fluorouracil, a chemotherapy staple, before it can act.

Cancer cells often survive chemotherapy by expelling it through membrane transporter proteins

3. Feeding tumor cells a metabolic escape route. 

A 2025 study found that chemotherapy itself can trigger this bodyguard response: treatment induces macrophages to ramp up CXCL7 production, which pushes a metabolic pathway (STAT1/PHGDH-driven serine synthesis) that both helps tumor cells survive treatment and reinforces the macrophages' own protective, tumor-favoring identity — a self-reinforcing feedback loop between drug exposure, tumor metabolism, and macrophage behavior.

STAT1/PHGDH-driven serine synthesis

4. Shielding cells from DNA damage. 

Beyond drug efflux and neutralization, TAMs support cancer cells' internal defenses too — boosting their <cite index="2-1">capacity for DNA repair, suppressing apoptosis (programmed cell death), and inducing protective autophagy</cite>, all of which help tumor cells absorb chemotherapy-induced damage without dying.

5. Guarding specific drug classes. 

Even classic, decades-old chemotherapy drugs aren't exempt. Macrophage-derived signals involving nitric oxide and sphingolipid metabolism have been linked to resistance against cisplatin, one of the most widely used chemotherapy agents in solid tumors.

Why this matters clinically-Why its important to Understand Tumor deference to Chemo

This isn't a peripheral finding — it may help explain a pattern oncologists have long observed: initial chemotherapy response followed by relapse, even when the tumor cells themselves haven't obviously mutated into resistant clones. <cite index="4-1">Higher infiltration of M2-like macrophages is consistently linked to worse clinical outcomes</cite> across multiple cancer types, and mechanisms of chemoresistance can arise not just from the tumor cells themselves but from these supportive stromal partners.

Importantly, the tumor doesn't just recruit passive helpers — it actively converts them. <cite index="6-1">Preclinical studies show that TAMs, following exposure to antitumor agents, can be reprogrammed toward an immunosuppressive, pro-blood-vessel-growth phenotype through various mechanisms</cite>, meaning chemotherapy itself can inadvertently train the tumor's bodyguard force to be more effective.

Fighting back: Disarming the Cancer bodyguards

If macrophages are propping up tumor resistance, an obvious strategy is to target them alongside — or instead of — the cancer cells directly. Several approaches are now in various stages of development:

• Blocking macrophage recruitment/survival. The CSF1/CSF1R signaling axis is the most heavily studied target, since it's essential for macrophage survival and recruitment into tumors. <cite index="14-1">Various approaches targeting either the CSF1 ligand or the CSF1R receptor are currently in clinical development</cite>, and one such drug, pexidartinib, has already been approved for a macrophage-driven (though non-malignant) tumor of the joint. Encouragingly, <cite index="14-1">emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile</cite>, making them attractive to pair with existing treatments.

• "Reprogramming" rather than depleting. Instead of eliminating TAMs outright, newer strategies try to flip them back toward an anti-tumor state. A 2025 study of the covalent CSF1R inhibitor FF-10101 found it <cite index="10-1">reduced immunosuppressive TAMs while increasing antitumor TAMs in the tumor microenvironment, in turn boosting tumor-antigen-specific CD8+ T cells and significantly slowing tumor growth</cite> in animal models — evidence that shifting macrophage identity, not just removing macrophages, can restore treatment sensitivity.

• Combination approaches. In triple-negative breast cancer — a subtype notorious for chemo and immunotherapy resistance — a heavily macrophage-infiltrated, T-cell-poor microenvironment has been directly linked to standard-of-care treatment failure, spurring active research into anti-CSF1R therapy combined with chemo-immunotherapy regimens to convert these "cold" tumors into ones the immune system can actually fight.

The Bigger Lesson: Cancer Is an Ecosystem

For decades, cancer research understandably focused heavily on the cancer cell itself: its DNA, mutations, uncontrolled growth, and ability to spread.

Today, scientists increasingly view cancer as an ecosystem.

Cancer cells communicate with immune cells. Immune cells communicate with blood vessels. Fibroblasts alter the surrounding tissue. Signaling molecules pass messages between different cell populations. Together, these interactions can influence tumor growth and treatment response.

This broader view may help explain why two tumors that look similar under a microscope can sometimes respond differently to the same treatment.

What Does This Mean for the Future of Cancer Treatment?

The macrophage story points toward a future in which cancer treatment may target several parts of the tumor ecosystem at once.

Rather than focusing exclusively on destroying cancer cells, scientists are exploring combinations that could attack the tumor while also changing the environment that protects it.

The concept is simple to understand, even though the biology is remarkably complex: if the tumor has recruited cellular allies, perhaps treatment can be designed to remove the support those allies provide.

Researchers are still uncovering exactly which macrophage populations matter most in each cancer and which strategies can safely manipulate them. Much of the evidence comes from laboratory studies, animal models, and early clinical research, so promising findings do not automatically mean a new treatment is ready for routine patient care.

Final Thought

Cancer is not simply a group of cells growing out of control. It is a constantly changing community in which cancer cells communicate with—and sometimes manipulate—their surroundings.

Macrophages are a fascinating example. Cells designed to protect and repair the body can, under certain tumor conditions, become part of the support system that helps cancer survive.

Understanding these cellular relationships may eventually allow scientists to make cancer treatments more precise: not only attacking the tumor, but also disrupting the environment that helps it endure.

References

1. Larionova, I. et al. "Tumor-associated macrophages and cancer-associated fibroblasts confer chemoresistance to tumor cells." Frontiers in Cell and Developmental Biology, 2018. DOI: 10.3389/fcell.2018.00131
2. "Spatial organization of mediated-macrophage chemoprotective niches in solid tumors: A mathematical analysis." bioRxiv, 2024. DOI: 10.1101/2024.11.21.624654
3. Zhang, L. et al. "Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17/CXCL22–CCR4–ATF6–GRP78 axis." Cell Death and Disease, 14, 2023. DOI: 10.1038/s41419-023-06108-0
4. "Progress in the Research on the Role of Tumor-associated Macrophages in Drug-resistance and Treatment of Tumors." Xiehe Yixue Zazhi, 2022.
5. Liu, S. et al. "Chemotherapy-induced macrophage CXCL7 expression drives tumor chemoresistance via the STAT1/PHGDH-serine metabolism axis and SAM paracrine feedback to M2 polarization." Cell Death and Disease, 16, 2025. DOI: 10.1038/s41419-025-07712-y
6. "Targeting tumor-associated macrophages to reverse antitumor drug resistance." PMC, 2024. PMC11210230
7. "Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance." npj Precision Oncology, 2024.
8. "Nitric oxide, acid sphingomyelinase, and syntaxin 4 in TAM-mediated cisplatin resistance." Frontiers in Immunology, 2018. DOI link via Frontiers
9. Kanno, K. et al. "Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages." JCI Insight, January 2025. PMC11721313
10. "Anti-CSF-1R therapy with combined immuno-chemotherapy coordinates an adaptive immune response to eliminate macrophage-enriched triple negative breast cancers." bioRxiv, May 2025. PMC12191229
11. Cannarile, M.A. et al. "Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy." Journal for ImmunoTherapy of Cancer, 2017. DOI: 10.1186/s40425-017-0257-y

This post is intended for general audiences interested in cancer biology and is not medical advice. Consult an oncologist for information relevant to individual diagnosis or treatment.

Brian Opiyo ( KRCHN, BScN)